Navigation Links
OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
Date:6/9/2008

VANCOUVER, June 9 /PRNewswire/ - OncoGenex Technologies Inc. will present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference on June 11 at 3 p.m. ET at the New York Palace Hotel. OncoGenex' President and Chief Executive Officer, Scott Cormack, will provide a corporate overview at the conference, including an overview of the Company's most recent data presentations from the American Society of Clinical Oncology (ASCO) 2008 and the American Society of Clinical Oncology (ASCO) Genitourinary 2008 cancer conferences.

About OncoGenex

OncoGenex is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. OGX-427 has begun evaluation in Phase 1 clinical studies, while the third product candidate, OGX-225, has completed preclinical pharmacology studies. More information is available at http://www.oncogenex.ca.

Definitive Agreement to Merge

On May 28, 2008, Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) and OncoGenex Technologies Inc., jointly announced the signing of a definitive agreement to merge the two companies. The proposed transaction is subject to the approval of Sonus' and OncoGenex' shareholders and in the case of OncoGenex, court approval under the arrangement provisions of the Canada Business Corporations Act.

<
'/>"/>
SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
2. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
3. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
4. Gen-Probe to Webcast Presentation at Seventh Annual Needham Biotechnology and Medical Technology Conference
5. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
6. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
7. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
8. Hologic to Present at the Needham Seventh Annual Biotechnology and Medical Technology Conference
9. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
10. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
11. NxStage Medical to Present at William Blair Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... results and highlights for the quarter ended June 30, ... financial markets close. Regulus will host ... 2014, at 5:00 pm Eastern Daylight Time to discuss ...
(Date:7/30/2014)... July 30, 2014 W. R. ... release of the REVELERIS® Prep purification system ... preparative chromatographers, and other researchers to perform both ... single unit. , With the REVELERIS® Prep purification ... preparative chromatography modes with a simple touch of ...
(Date:7/30/2014)... A study presented at the 2014 ... of CSL Behring,s C1 Inhibitor (C1-INH) concentrate in ... sensitized patients. C1-INH is a human protein and ... The study shows that post-transplant treatment with ... of complement components 3 and 4, suggesting that ...
(Date:7/30/2014)...  Replikins Ltd. today released new data on changes ... the current outbreaks, the mean Ebola Reston gene Replikin ... 1995 and 2002 was 1.1; the mean Replikin Count ... in 2013, thus predicting the current outbreaks in humans. ... shown to be able to predict outbreaks (1).  For ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Grace Launches New REVELERIS® Prep Purification System 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... BEIJING , June 29 ... ("China Agritech", or the "Company"), a leading organic,compound fertilizer ... it has received $10 million as a ... Carlyle Asia Growth Partners IV, L.P. and CAGP IV,Co-Investment, ...
... 28, 2010 "More than meets the eye" may soon ... popular robotic toys. Researchers at Harvard and MIT have ... that rely on the ancient art of origami. Called ... thin sheet composed of interconnected triangular sections could transform itself ...
... ... effective renewable materials for customers which reduce dependency on fossil fuels, DuPont Applied ... portfolio of biomaterials and biofuels to global markets at the BIO World Congress ... ...
Cached Biology Technology:China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group 2China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group 3China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group 4Shape-shifting sheets automatically fold into multiple shapes 2DuPont Leader: Global Demand for Renewable Innovations Growing 2DuPont Leader: Global Demand for Renewable Innovations Growing 3
(Date:7/30/2014)... research from Bjorn Brembs, professor of neurogenetics at the ... proof-of-concept figure allowing readers and reviewers to run the ... an important leap forward for scientific publishing, by demonstrating ... a scholarly output. , Figure 3 in fact doesn,t ... code to F1000Research , and the figure is ...
(Date:7/30/2014)... use of iodine-125 (125I) in cancer treatment has ... root ganglia are critical for neural transmission between ... Zhang and colleagues from Institute of Radiation Medicine, ... 125I could be implanted into rat dorsal root ... 125I seeds with different radioactivity (0, 14.8, 29.6 ...
(Date:7/30/2014)... Calif. , July 30, 2014 ... with the United States Air Force Research Laboratory ... by Binghamton University to ... performance monitoring (HPM). The $425,000 project, with contributions ... packaging firm i3 Electronics, Inc. ( Endicott, ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... of Economic Development (GOED) and the Desert Research Institute ... to evaluate the capabilities of big data analytics and ... This will serve as a basis for a new ... workforce and economic development across the Silver State. ...
... - Scarring of the airways can lead to long-term ... of chlorine gas from events such as an industrial ... chemical warfare. Household mishaps from mixing bleach with acidic ... if this occurs in a poorly ventilated space, chlorine ...
... that the bacteria that colonize the gastrointestinal tract of mammals ... of the University of Nebraska show that changes in cholesterol ... research was published online ahead of print in the journal ... study, the researchers added plant sterol esters to the diets ...
Cached Biology News:Desert Research Institute utilizing IBM big data analytics to assist Nevada's growth strategy 2Desert Research Institute utilizing IBM big data analytics to assist Nevada's growth strategy 3Desert Research Institute utilizing IBM big data analytics to assist Nevada's growth strategy 4UofL scientist uncovers how airway cells regenerate after chlorine gas injury 2Host cholesterol secretion likely to influence gut microbiota 2
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
... polyclonal antibody raised against a ... Immunogen: SF3B2 (NP_006833, ... partial recombinant protein with GST ... Number: NM_006842 ...
...
Biology Products: